Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results

Article Medicine, General & Internal

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

M. R. Bishop et al.

Summary: Tisagenlecleucel did not demonstrate superiority over standard salvage therapy in this trial. Further studies are needed to evaluate which patients may benefit the most from each approach.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster et al.

Summary: The JULIET trial evaluated the long-term treatment outcomes and safety of tisagenlecleucel in adult patients, showing durable activity and manageable safety profiles in patients with relapsed or refractory aggressive B-cell lymphomas. Tisagenlecleucel compared favorably with conventional therapeutic approaches for patients with large B-cell lymphomas that are refractory to chemoimmunotherapy or relapsing after second-line therapies.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology